320 related articles for article (PubMed ID: 16765660)
1. Alterations in canine vertebral bone turnover, microdamage accumulation, and biomechanical properties following 1-year treatment with clinical treatment doses of risedronate or alendronate.
Allen MR; Iwata K; Phipps R; Burr DB
Bone; 2006 Oct; 39(4):872-9. PubMed ID: 16765660
[TBL] [Abstract][Full Text] [Related]
2. Bone remodeling at the iliac crest can predict the changes in remodeling dynamics, microdamage accumulation, and mechanical properties in the lumbar vertebrae of dogs.
Mashiba T; Hui S; Turner CH; Mori S; Johnston CC; Burr DB
Calcif Tissue Int; 2005 Sep; 77(3):180-5. PubMed ID: 16265598
[TBL] [Abstract][Full Text] [Related]
3. Three years of alendronate treatment results in similar levels of vertebral microdamage as after one year of treatment.
Allen MR; Burr DB
J Bone Miner Res; 2007 Nov; 22(11):1759-65. PubMed ID: 17663638
[TBL] [Abstract][Full Text] [Related]
4. Bisphosphonate treatment affects trabecular bone apparent modulus through micro-architecture rather than matrix properties.
Day JS; Ding M; Bednarz P; van der Linden JC; Mashiba T; Hirano T; Johnston CC; Burr DB; Hvid I; Sumner DR; Weinans H
J Orthop Res; 2004 May; 22(3):465-71. PubMed ID: 15099622
[TBL] [Abstract][Full Text] [Related]
5. Low bone mineral density is associated with bone microdamage accumulation in postmenopausal women with osteoporosis.
Stepan JJ; Burr DB; Pavo I; Sipos A; Michalska D; Li J; Fahrleitner-Pammer A; Petto H; Westmore M; Michalsky D; Sato M; Dobnig H
Bone; 2007 Sep; 41(3):378-85. PubMed ID: 17597017
[TBL] [Abstract][Full Text] [Related]
6. Effects of minodronic acid and alendronate on bone remodeling, microdamage accumulation, degree of mineralization and bone mechanical properties in ovariectomized cynomolgus monkeys.
Yamagami Y; Mashiba T; Iwata K; Tanaka M; Nozaki K; Yamamoto T
Bone; 2013 May; 54(1):1-7. PubMed ID: 23356990
[TBL] [Abstract][Full Text] [Related]
7. Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles.
Mashiba T; Turner CH; Hirano T; Forwood MR; Johnston CC; Burr DB
Bone; 2001 May; 28(5):524-31. PubMed ID: 11344052
[TBL] [Abstract][Full Text] [Related]
8. Changes in vertebral strength-density and energy absorption-density relationships following bisphosphonate treatment in beagle dogs.
Allen MR; Burr DB
Osteoporos Int; 2008 Jan; 19(1):95-9. PubMed ID: 17710353
[TBL] [Abstract][Full Text] [Related]
9. Greater magnitude of turnover suppression occurs earlier after treatment initiation with risedronate than alendronate.
Allen MR; Turek JJ; Phipps RJ; Burr DB
Bone; 2011 Jul; 49(1):128-32. PubMed ID: 20637914
[TBL] [Abstract][Full Text] [Related]
10. Sequential treatment of ovariectomized mice with bFGF and risedronate restored trabecular bone microarchitecture and mineralization.
Yao W; Balooch G; Balooch M; Jiang Y; Nalla RK; Kinney J; Wronski TJ; Lane NE
Bone; 2006 Sep; 39(3):460-9. PubMed ID: 16713415
[TBL] [Abstract][Full Text] [Related]
11. Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib.
Mashiba T; Hirano T; Turner CH; Forwood MR; Johnston CC; Burr DB
J Bone Miner Res; 2000 Apr; 15(4):613-20. PubMed ID: 10780852
[TBL] [Abstract][Full Text] [Related]
12. Effects of alendronate and risedronate on bone material properties in actively forming trabecular bone surfaces.
Hofstetter B; Gamsjaeger S; Phipps RJ; Recker RR; Ebetino FH; Klaushofer K; Paschalis EP
J Bone Miner Res; 2012 May; 27(5):995-1003. PubMed ID: 22336962
[TBL] [Abstract][Full Text] [Related]
13. Risedronate and alendronate suppress osteocyte apoptosis following cyclic fatigue loading.
Follet H; Li J; Phipps RJ; Hui S; Condon K; Burr DB
Bone; 2007 Apr; 40(4):1172-7. PubMed ID: 17240209
[TBL] [Abstract][Full Text] [Related]
14. Biomechanical effects of teriparatide in women with osteoporosis treated previously with alendronate and risedronate: results from quantitative computed tomography-based finite element analysis of the vertebral body.
Chevalier Y; Quek E; Borah B; Gross G; Stewart J; Lang T; Zysset P
Bone; 2010 Jan; 46(1):41-8. PubMed ID: 19800436
[TBL] [Abstract][Full Text] [Related]
15. Changes in non-enzymatic glycation and its association with altered mechanical properties following 1-year treatment with risedronate or alendronate.
Tang SY; Allen MR; Phipps R; Burr DB; Vashishth D
Osteoporos Int; 2009 Jun; 20(6):887-94. PubMed ID: 18850239
[TBL] [Abstract][Full Text] [Related]
16. The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates.
Balena R; Toolan BC; Shea M; Markatos A; Myers ER; Lee SC; Opas EE; Seedor JG; Klein H; Frankenfield D
J Clin Invest; 1993 Dec; 92(6):2577-86. PubMed ID: 8254015
[TBL] [Abstract][Full Text] [Related]
17. Density and structural changes in the bone of growing rats after weekly alendronate administration with and without a methotrexate challenge.
Spadaro JA; Damron TA; Horton JA; Margulies BS; Murray GM; Clemente DA; Strauss JA
J Orthop Res; 2006 May; 24(5):936-44. PubMed ID: 16609966
[TBL] [Abstract][Full Text] [Related]
18. The effect of risedronate on bone mineralization as measured by micro-computed tomography with synchrotron radiation: correlation to histomorphometric indices of turnover.
Borah B; Ritman EL; Dufresne TE; Jorgensen SM; Liu S; Sacha J; Phipps RJ; Turner RT
Bone; 2005 Jul; 37(1):1-9. PubMed ID: 15894527
[TBL] [Abstract][Full Text] [Related]
19. Bisphosphonates alter trabecular bone collagen cross-linking and isomerization in beagle dog vertebra.
Allen MR; Gineyts E; Leeming DJ; Burr DB; Delmas PD
Osteoporos Int; 2008 Mar; 19(3):329-37. PubMed ID: 18094911
[TBL] [Abstract][Full Text] [Related]
20. Raloxifene enhances vertebral mechanical properties independent of bone density.
Allen MR; Iwata K; Sato M; Burr DB
Bone; 2006 Nov; 39(5):1130-1135. PubMed ID: 16814622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
